Physician profile
Hussein Khan
NPI 1023428398
$2,583.11
in general payments reported to CMS, 2019-2025
22 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $337 · 2024: $797 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $391.92 | 2023-2025 | Breztri, Fasenra, Airsupra |
| Viiv Healthcare Company | $387.02 | 2024-2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.22 | 2024-2025 | Jardiance |
| Abbvie INC. | $249.46 | 2023-2025 | |
| Exact Sciences Corporation | $191.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $160.01 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $156.78 | 2023-2025 | Dificid, Winrevair |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.57 | 2023-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $150.14 | 2025 | Yeztugo |
| Intercept Pharmaceuticals, INC. | $69.48 | 2024-2025 | |
| Astellas Pharma US INC | $61.47 | 2025 | Veozah |
| Genzyme Corporation | $59.06 | 2024-2025 | |
| Hologic Sales and Service, LLC | $58.86 | 2024 | Aptima |
| Phathom Pharmaceuticals, INC. | $50.39 | 2024-2025 | Voquezna |
| Amgen INC. | $25.82 | 2025 | Tavneos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $25.74 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $23.80 | 2024 | Nuedexta |
| Pfizer INC. | $23.31 | 2023 | |
| Phadia US INC. | $20.11 | 2025 | Immunocap |
| Idorsia Pharmaceuticals US INC | $15.44 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $13.74 | 2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.